| Completed | 3 | 1718 | Europe | Modified Process Hepatitis B Vaccine (Experimental), Hepatitis B Vaccine (Recombinant), RECOMBIVAX HB™, ENGERIX-B® | Merck Sharp & Dohme LLC | Hepatitis B | 10/07 | 10/07 | | |
NCT00440531: Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) |
|
|
| Completed | 3 | 540 | NA | Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), Comparator: Modified Process Hepatitis B Vaccine (Experimental), Comparator: ENGERIX-B™ (currently licensed product) | Merck Sharp & Dohme LLC | Hepatitis B | 11/07 | 11/07 | | |
NCT01463683: Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) |
|
|
| Completed | 3 | 722 | NA | 2XP HEPTAVAX™-II SC, RECOMBIVAX HB, HBVAXPRO, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM | Merck Sharp & Dohme LLC | Hepatitis B | 11/12 | 11/12 | | |
2004-005023-18: Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade |
|
|
| Completed | 3 | 500 | Europe | Hepatitis B Vaccine (Recombinant) Upgraded Process, RecombivaxHB(HBVAXPRO), HBV-UP, NA, HBVAXPRO (Referred to as REcombivaxHB in Protocol, HBVAXPRO (Referred to as REcombivaxHB in Protocol | Merck Sharp & Dohme (Sweden) AB, Merck & Co., Inc, Suomen MSD Oy | Acute hepatitis B without delta-agent and without hepatic coma | | 05/06 | | |